Should You Buy Neubase Therapeutics Inc (NBSE) Stock on Friday?

Neubase Therapeutics Inc (NBSE) stock has gained 33.82% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Neubase Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NBSE!

See Full NBSE Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With NBSE Stock Today?

Neubase Therapeutics Inc (NBSE) stock is down -8.15% while the S&P 500 is up 0.53% as of 1:13 PM on Friday, Dec 1. NBSE is lower by -$0.08 from the previous closing price of $0.99 on volume of 1,268,385 shares. Over the past year the S&P 500 has gained 12.55% while NBSE is lower by -81.00%. NBSE lost -$7.78 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Neubase Therapeutics Inc click here.

More About Neubase Therapeutics Inc

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others. Click Here to get the full Stock Report for Neubase Therapeutics Inc stock.